0
Episode209 of 511
Længde10M
SprogEngelsk
FormatKategori
The AstraZeneca- Oxford university COVID-19 vaccine has been paused by a number of countries in Europe after reports of blood clotting and Deep Vein Thrombosis in some participants arose. Countries including France Germany, Italy, Spain, Portugal and Norway have put a halt on the rollout of the innoculation programme for now and are examining the cases that have occurred.
While they carry out assessments, the World Health Organisation as well as the European Union’s vaccine regulator have played down the issue for now. They have highlighted two important points. One, there is no indication that the vaccine is linked to an increased risk of blood clots. Two, the number of cases in vaccinated people was no higher than in the general population.
In India, the Serum Institute of India is manufacturing the Oxford-AstraZeneca vaccine as Covishield and 1.5 crore doses have already been administered.
At a time when COVID-19 cases have seen a spike across India and Europe and the vaccination process is underway, a number of key questions have emerged. Why has this become an issue in the EU? Should India, which manufactures the same vaccine, be worried?
The Quint spoke with Dr Rahul Bhargava, Director and Head, Haematology and Bone Marrow Transplant at Fortis Memorial Research Institute, Gurugram
Learn more about your ad choices. Visit megaphone.fm/adchoices
Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis
Lyt og læs så meget du har lyst til
Opdag et kæmpe bibliotek fyldt med fortællinger
Eksklusive titler + Mofibo Originals
Opsig når som helst
Om Mofibo
Jobs
nye app-funktioner
Investor Relations
Presse
Bæredygtighed
Tilgængelighedserklæring
Whistleblow
Søg
Bøger
Bogserier
Mofibo Originals
Podcasts
Forfattere
Indlæsere
Kategorier
Hjælpecenter
Abonnementer
Køb gavekort
Indløs gavekort
Indløs kampagnekode
Studierabat
Dansk
Danmark
Privatlivspolitik
Medlemsvilkår
Cookies
